Changes in psychotropic polypharmacy and high-potency prescription following policy change: Findings from a large scale Japanese claims database.

Takeshima, Masahiro; Enomoto, Minori; Ogasawara, Masaya; Kudo, Mizuki; Itoh, Yu; Yoshizawa, Kazuhisa; Fujiwara, Dai; Takaesu, Yoshikazu; Mishima, Kazuo

Takeshima, Masahiro; Enomoto, Minori; Ogasawara, Masaya; Kudo, Mizuki; Itoh, Yu; Yoshizawa, Kazuhisa; Fujiwara, Dai; Takaesu, Yoshikazu; Mishima, Kazuo.

Afiliação

Takeshima M; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Enomoto M; Department of Medical Technology, School of Health Sciences, Tokyo University of Technology, Tokyo, Japan.
Ogasawara M; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Kudo M; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Itoh Y; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Yoshizawa K; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Fujiwara D; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Takaesu Y; Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Mishima K; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.

Psychiatry Clin Neurosci ; 76(9): 475-477, 2022 09.

Article em En | MEDLINE | ID: mdl-35655425

Assuntos

Polimedicação; Psicotrópicos; Humanos; Japão; Políticas; Prescrições; Psicotrópicos/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicotrópicos / Polimedicação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google